Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

zoetis animal health aps - methylprednisolon - tabletter - 4 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - methylprednisolonnatriumsuccinat, methylprednisolonsuccinat - pulver og solvens til injektionsvæske, opløsning - 40 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

cp-pharma handelsgesellschaft mbh - prednisolon - tabletter - 50 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterone acetat - prostatiske neoplasmer - endokrine terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - abiraterone acetat - prostatiske neoplasmer - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

krka, d.d., novo mesto - abiraterone acetat - prostatiske neoplasmer - endokrine terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - olaparib - Æggestokkene neoplasmer - antineoplastiske midler - Æggestokkene cancerlynparza er angivet som monoterapi til:vedligeholdelse behandling af voksne patienter med avanceret (figo faser iii og iv) brca1/2-muterede (germline og/eller somatiske) high-grade epitelial ovariecancer, æggeleder eller primær peritoneal cancer, der er i reaktion (hel eller delvis) efter afslutningen af første linje platin-baseret kemoterapi. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 og 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. patienter bør have, der tidligere er blevet behandlet med en antracyklin og en taxane i (neo)adjuvans eller metastatisk indstilling, medmindre patienter, der ikke var egnet til disse behandlinger (se afsnit 5. patienter med hormon receptor (hr)-positiv brystkræft bør også have udviklet sig på eller efter forudgående endokrine terapi, eller anses uegnet til at endokrine terapi. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

elanco gmbh - miconazolnitrat, polymyxin b sulfat, prednisolonacetat - øredråber, suspension og kutansuspension - 5 + 23 + 0,529 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastiske midler - bryst cancerdocetaxel kabi i kombination med doxorubicin og cyclophosphamid er angivet for den adjuverende behandling af patienter med:betjenes node-positiv brystkræft;betjenes node-negativ brystkræft. for patienter med betjenes node-negativ brystkræft, adjuverende behandling bør begrænses til patienter, der er berettiget til at modtage kemoterapi i henhold til internationalt anerkendte kriterier for primære behandling af tidlig brystkræft. docetaxel kabi i kombination med doxorubicin er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft, der ikke tidligere har modtaget cytotoksisk behandling for denne tilstand. docetaxel kabi monoterapi er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft efter svigt af cytotoksiske terapi. tidligere kemoterapi skulle have inkluderet et anthracyclin eller et alkyleringsmiddel. docetaxel kabi i kombination med trastuzumab er indiceret til behandling af patienter med metastatisk brystcancer, hvis tumorer overexpress her2, og som ikke tidligere har modtaget kemoterapi for metastatisk sygdom. docetaxel kabi i kombination med capecitabin, er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft efter svigt af cytotoksisk kemoterapi. tidligere behandling skulle have inkluderet en antracyklin. non-small-cell lung cancerdocetaxel kabi er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk ikke-small-cell lung cancer efter svigt af før kemoterapi. docetaxel kabi i kombination med cisplatin er indiceret til behandling af patienter med inoperabel lokalt fremskreden eller metastatisk ikke-small-cell lung cancer hos patienter, der ikke tidligere har modtaget kemoterapi for denne tilstand. prostate cancerdocetaxel kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer. docetaxel kabi i kombination med androgen-afsavn terapi (adt), med eller uden prednison eller prednisolon, er indiceret til behandling af patienter med metastatisk hormon-følsomme prostatakræft. gastrisk adenocarcinomadocetaxel kabi i kombination med cisplatin og 5-fluorouracil er indiceret til behandling af patienter med metastatisk gastrisk adenocarcinom, herunder adenocarcinoma af gastroøsofageal vejkryds, der ikke har modtaget forudgående kemoterapi for metastatisk sygdom. hoved og hals cancerdocetaxel kabi i kombination med cisplatin og 5-fluorouracil er indiceret til induktion behandling af patienter med lokalt fremskreden pladecellekræft i hoved og hals.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

chanelle pharmaceuticals manufacturing limited - miconazolnitrat, polymyxin b sulfat, prednisolonacetat - øredråber, suspension - 23 mg/ml+5 mg/ml+5500 ie/ml